Oracle Unveils New Version of Oracle Health Sciences ClearTrial Plan and Source Cloud Service - Applied Clinical Trials

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
Oracle Unveils New Version of Oracle Health Sciences ClearTrial Plan and Source Cloud Service

Source: Company News Release

Cloud-Based Clinical Trial Operations Software Delivers Enhanced Planning, Sourcing, and Tracking Capabilities to Support Phase I Trials and Complex Multi-Arm Studies

Oracle Health Sciences today announced the availability of Oracle Health Sciences ClearTrial Plan and Source Cloud Service 5.0, the latest version of the cloud-based clinical trial operations solution that enables life sciences organizations to plan, source and track clinical projects and financial performance via a single, integrated platform.

The newest release now provides support for phase I trials, which when combined with existing capabilities, enables organizations to support a broad range of clinical trials – from initial safety screenings to complex testing and post-approval studies – in one scalable and flexible solution.

Further expanding the breadth and study types that sponsors and contract research organizations (CROs) can create and track, the latest release also provides support for multiple treatment arm studies – including complex cross over studies, in which different types and sequences of treatment courses are administered to various study groups.

Oracle Health Sciences ClearTrial Plan and Source is now delivered via the Oracle Health Sciences Cloud, providing users with improved performance, availability and fault tolerance. In addition, as a cloud-based solution, users will gain immediate access to ClearTrial’s enhanced functionality and improved user interface. 

“We remain committed to evolving the breadth and depth of Oracle ClearTrial Plan and Source Cloud Service’s capabilities to provide life sciences organizations with the tools they need to conduct and track increasingly complex clinical trials across diverse geographies, outsourcers, therapeutic areas and trial phases,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences.  “The new capabilities will allow life sciences organizations to gain a competitive edge in the marketplace while accelerating the process of bringing new therapies to market.”

Related Links

Managing Budgets in Complex Times with Tight Variances

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
94%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
6%
View Results
Untitled Document
Source: Company News Release,
Click here